Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Eppendorf North America’s Mastercycler Nexus X1 provides researchers with increased heating and cooling rates by uniting the software with a fast 96-well block. All this is achieved while maintaining low power consumption and low noise emission levels, making the instrument suitable for life science laboratories.
Audit MicroControls’ MicroLQ serum protein control, two levels, is intended to simulate human patient serum samples to monitor the precision of laboratory testing procedures for albumin, alpha1-acid glycoprotein, alpha1-antitrypsin, alpha2-macroglobulin, antithrombin, beta2 microglobulin, ceruloplasmin, complement C3, complement C4, haptoglobin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin M, prealbumin, total protein, and transferrin.
Pathwork Diagnostics has entered into an agreement with Kindstar Global to provide Kindstar with the FDA-cleared IVD kit version of the Pathwork Tissue of Origin Test. The agreement expands Pathwork’s international network of test and service providers and is the first IVD kit agreement for Pathwork.
CellaVision’s proficiency software is for clinical laboratories that assess and perform the classification of blood cells and accredited providers of external quality assessment schemes for laboratory medicine. With the software, medical technologists can train and test their skills in performing peripheral blood and body fluid differential counts and get instant feedback on their performance.
BioFire Diagnostics announced that the U.S. Patent and Trademark Office has issued U.S. patent No. 8,394,608 covering the company’s FilmArray system. This is the first U.S. patent issued to cover the FilmArray system, and BioFire has exclusive rights to the patented technology. The patent specifically covers methods for sample preparation and two-step multiplex polymerase chain reaction in a sealed container.
Hardy Diagnostics’ Val media-fill challenge kits are for USP 797 compliance testing for compounding-sterile preparations (CSPs). The ready-to-use media-fill challenge kits are for use in validating pharmacy compounding personnel in accordance with USP 797 guidelines. Aseptic media-fill testing is part of an effective quality assurance program to ensure pharmaceutical processes and personnel produce sterile products that are free of microbial contaminants.
Randox Laboratories’ Acusera liquid BNP control is for use in the routine monitoring of accuracy and precision. Assayed instrument-specific target values and ranges are provided for Beckman Access, Abbott Architect, and Siemens Advia Centaur instruments. The BNP control is a 100 percent human serum, manufactured to the high-quality standards associated with all Acusera controls.
Life Technologies has signed a collaborative research agreement and related license with Harvard University under which Life Tech has acquired exclusive rights to develop a panel of characterization assays to rapidly evaluate human pluripotent stem cells for their utility in discovery and translational research applications.
Diagnovus has launched Engauge-cancer-DLBCL, a commercial gene-expression assay for risk stratification and treatment of patients with diffuse large B-cell lymphoma. “Engauge-cancer-DLBCL, which combines a patient’s IPI [International Prognostic Index] score and the results of the gene-expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients,” Ron Levy, MD, leader of the Lymphoma Program at Stanford University School of Medicine, said in a statement.
NanoString Technologies has launched its first commercial IVD product, the Prosigna breast cancer prognostic gene signature assay for the nCounter diagnostic system, in the European Union and Israel. Based on the PAM50 gene signature initially discovered by Charles Perou, PhD, and colleagues, the Prosigna assay provides a subtype classification based on the biology of an individual’s breast tumor (intrinsic subtyping), and a prognostic score (risk of recurrence, or ROR, score).
